Common use of Pre-injection Testing Clause in Contracts

Pre-injection Testing. Prior to the first injection of Biomethane into the LDC System, or other NW Natural owned and operated facilities, Producer will hire an independent certified third party laboratory (Oregon Environmental Laboratory Accreditation Program [ORELAP] certified, or equivalent in another state, where applicable) to perform two pre-injection tests (“Pre-Injection Testing”). Samples for each test will be taken a minimum of fourteen (14) days apart and from the flow of gas to the Receipt Point Facilities prior to receipt of Biomethane at the Receipt Point Facilities. Producer will provide NW Natural with a minimum of two (2) business days’ advance notice of the Biomethane sampling and NW Natural will have the option to have a representative present to observe the samples being taken. Samples will be tested for all Constituents specified in Table 1 in Exhibit C according to the feedstock. Test results will be shared with NW Natural within five (5) business days of Producer's receipt of the test results. Producer is responsible for identifying an independent third-party certified laboratory that is capable of detecting constituents at levels specified in Table 1 – Constituent Concentrations, attached in Exhibit C. NW Natural reserves the right to specify a certified laboratory in the event Producer is unable to do so. Test results from the second pre-injection test will identify the Group 1 and Group 2 Health Constituents for Periodic Testing. During Pre-Injection Testing, the Biomethane’s collective potential cancer risk and non-cancer risk totals will be calculated for the Group 2 Health Constituents: Cancer Risk: the sum of the ratios for each carcinogenic constituent measured over the Trigger Level identified in Table 1 in Exhibit C. The ratio is the measured value divided by the trigger level (See formula in Table 2 in Exhibit C). Non-Cancer Risk: the sum of the health indexes of each non-carcinogenic constituent that registers over the Trigger Level identified in Table 1 in Exhibit C. The health index is the measured value divided by the Trigger Level multiplied by 0.1 (See formula in Table 2 in Exhibit C). If the collective potential cancer risk or non-cancer risk is at or above the Risk Level A values defined in Table 2 - Collective Risk from Carcinogenic and Non-carcinogenic Constituents, attached in Exhibit C, the Biomethane cannot be accepted or transported by the LDC System. Producer will make necessary modifications to lower the collective potential cancer risk or non-cancer risk below the Risk Level A values and restart Pre-Injection Testing after a minimum seven (7) day period from the last testing sampling. If during Pre-Injection Testing, any Pipeline Integrity Protective Constituent is found to be at or above the Trigger Level identified in Table 1 in Exhibit C, the Biomethane cannot be accepted or transported by the LDC system. Producer will make necessary modifications to lower the concentration value below the Trigger Level and restart Pre-Injection Testing after a minimum seven (7) day period from the last testing sampling. If all Pipeline Integrity Protective Constituents are found to be below the Trigger Levels identified in Table 1 in Exhibit C, all Health Protective Constituents are measured below the Upper Action Levels identified in Table 1 in Exhibit C, and both the collective potential cancer risk total and the collective non-cancer risk total from the Group 2 Health Protective Constituents are below the Risk Level A values identified in Table 2 in Exhibit C, in each case in two consecutive pre-injection tests, the Biomethane may be injected subject to compliance with the Periodic Testing (as defined below) requirements specified in Section 4.6. The costs of Pre-Injection Testing, as well as any required subsequent testing, will be borne by Producer. If the test results from the first pre-injection sample set do not identify any Health Protective Constituents above the Upper Action Levels or Pipeline Integrity Constituents above the Trigger Levels and the Gas Quality Parameters are below the Action Levels, the Biomethane may be injected into the Receipt Point Facilities while the results for the second sample set are evaluated. If the results from the second pre-injection sample set indicate a constituent is outside the acceptable limit as specified in Table 1 in Exhibit C, the Biomethane will be shut-off and Producer will make necessary modifications to lower the concentration value below the Trigger Level and restart Pre-Injection Testing after a minimum seven (7) day period from the last testing sampling. Pre-injection Testing will not be performed until the Receipt Point Facilities have been constructed, tested, and commissioned by NW Natural.

Pre-injection Testing. Prior to the first injection of Biomethane into the LDC System, or other NW Natural owned and operated facilities, Producer will hire an independent certified third party laboratory (Oregon Environmental Laboratory Accreditation Program [ORELAP] certified, or equivalent in another state, where applicable) to perform two pre-injection tests (“Pre-Injection Testing”). Samples for each test will be taken a minimum of fourteen (14) days apart and from the flow of gas to the Receipt Point Facilities prior to receipt of Biomethane at the Receipt Point Facilities. Producer will provide NW Natural with a minimum of two (2) business days’ advance notice of the Biomethane sampling and NW Natural will have the option to have a representative present to observe the samples being taken. Samples will be tested for all Constituents specified in Table 1 in Exhibit C according to the feedstock. Test results will be shared with NW Natural within five (5) business days of Producer's receipt of the test results. . a) Producer is responsible for identifying an independent third-party certified laboratory that is capable of detecting constituents at levels specified in Table 1 – Constituent Concentrations, attached in Exhibit C. NW Natural reserves the right to specify a certified laboratory in the event Producer is unable to do so. . b) Test results from the second pre-injection test will identify the Group 1 and Group 2 Health Constituents for Periodic Testing. . c) During Pre-Injection Testing, the Biomethane’s collective potential cancer risk and non-non- cancer risk totals will be calculated for the Group 2 Health Constituents: : i. Cancer Risk: the sum of the ratios for each carcinogenic constituent measured over the Trigger Level identified in Table 1 in Exhibit C. The ratio is the measured value divided by the trigger level (See formula in Table 2 in Exhibit C). ii. Non-Cancer Risk: the sum of the health indexes of each non-carcinogenic constituent that registers over the Trigger Level identified in Table 1 in Exhibit C. The health index is the measured value divided by the Trigger Level multiplied by 0.1 (See formula in Table 2 in Exhibit C). . d) If the collective potential cancer risk or non-cancer risk is at or above the Risk Level A values defined in Table 2 - Collective Risk from Carcinogenic and Non-carcinogenic Constituents, attached in Exhibit C, the Biomethane cannot be accepted or transported by the LDC System. Producer will make necessary modifications to lower the collective potential cancer risk or non-cancer risk below the Risk Level A values and restart Pre-Injection Testing after a minimum seven (7) day period from the last testing sampling. . e) If during Pre-Injection Testing, any Pipeline Integrity Protective Constituent is found to be at or above the Trigger Level identified in Table 1 in Exhibit C, the Biomethane cannot be accepted or transported by the LDC system. Producer will make necessary modifications to lower the concentration value below the Trigger Level and restart Pre-Injection Testing after a minimum seven (7) day period from the last testing sampling. . f) If all Pipeline Integrity Protective Constituents are found to be below the Trigger Levels identified in Table 1 in Exhibit C, all Health Protective Constituents are measured below the Upper Action Levels identified in Table 1 in Exhibit C, and both the collective potential cancer risk total and the collective non-cancer risk total from the Group 2 Health Protective Constituents are below the Risk Level A values identified in Table 2 in Exhibit C, in each case in two consecutive pre-injection tests, the Biomethane may be injected subject to compliance with the Periodic Testing (as defined below) requirements specified in Section 4.6. . g) The costs of Pre-Injection Testing, as well as any required subsequent testing, will be borne by Producer. . h) If the test results from the first pre-injection sample set do not identify any Health Protective Constituents above the Upper Action Levels or Pipeline Integrity Constituents above the Trigger Levels and the Gas Quality Parameters are below the Action Levels, the Biomethane may be injected into the Receipt Point Facilities while the results for the second sample set are evaluated. If the results from the second pre-injection sample set indicate a constituent is outside the acceptable limit as specified in Table 1 in Exhibit C, the Biomethane will be shut-shut- off and Producer will make necessary modifications to lower the concentration value below the Trigger Level and restart Pre-Injection Testing after a minimum seven (7) day period from the last testing sampling. . i) Pre-injection Testing will not be performed until the Receipt Point Facilities have been constructed, tested, and commissioned by NW Natural.

Pre-injection Testing. Prior to the first injection of Biomethane into the NW Natural’s LDC System, or other NW Natural owned and operated facilities, the Producer will hire an independent certified third party laboratory (Oregon Environmental Laboratory Accreditation Program [ORELAP] certified, or equivalent in another state, where applicable) to perform two pre-injection tests (“Pre-Injection Testing”)tests. Samples for each test will be taken a minimum of fourteen (14) calendar days apart and from the flow of gas to the Receipt Point Facilities prior to receipt of Biomethane at the Receipt Point Facilities. Producer will shall provide NW Natural with a minimum of two (2) business days’ advance notice of the Biomethane sampling and NW Natural will shall have the option to have a representative present to observe the samples being taken. Samples will shall be tested for all Constituents specified in Table 1 in Exhibit C according to the feedstock. Test results will shall be shared with NW Natural within five (5) business days of Producer's receipt of the test results. . a) The Producer is responsible for identifying an independent third-party certified laboratory that is capable of detecting constituents at levels specified in Table 1 – Constituent Concentrations, attached in Exhibit C. NW Natural reserves the right to specify a certified laboratory in the event the Producer is unable to do so. . b) Test results from the second pre-injection test will identify the Group 1 and Group 2 Health Constituents for Periodic Testing. . c) During Prepre-Injection Testinginjection testing, the Biomethane’s collective potential cancer risk and non-cancer risk totals will shall be calculated for the Group 2 Health Constituents: : i. Cancer Risk: the sum of the ratios for each carcinogenic constituent measured over the Trigger Level identified in Table 1 in Exhibit C. The ratio is the measured value divided by the trigger level (See formula in Table 2 in Exhibit C). ii. Non-Cancer Risk: the sum of the health indexes of each non-carcinogenic constituent that registers over the Trigger Level identified in Table 1 in Exhibit C. The health index is the measured value divided by the Trigger Level multiplied by 0.1 (See formula in Table 2 in Exhibit C). . d) If the collective potential cancer risk or non-cancer risk is at or above the Risk Level A values defined in Table 2 - Collective Risk from Carcinogenic and Non-carcinogenic Constituents, attached in Exhibit C, the Biomethane cannot be accepted or transported by the LDC SystemNW Natural's pipeline system. Producer will shall make necessary modifications to lower the collective potential cancer risk or non-cancer risk below the Risk Level A values and restart Prepre-Injection Testing injection testing after a minimum seven (7) calendar-day period from the last testing sampling. . e) If during Prepre-Injection Testinginjection testing, any Pipeline Integrity Protective Constituent is found to be at or above the Trigger Level identified in Table 1 in Exhibit C, the Biomethane cannot be accepted or transported by the LDC NW Natural's pipeline system. The Producer will shall make necessary modifications to lower the concentration value below the Trigger Level and restart Prepre-Injection Testing injection testing after a minimum seven (7) calendar-day period from the last testing sampling. . f) If all Pipeline Integrity Protective Constituents are found to be below the Trigger Levels identified in Table 1 in Exhibit C, all Health Protective Constituents are measured below the Upper Action Levels identified in Table 1 in Exhibit C, and both the collective potential cancer risk total and the collective non-cancer risk total from the Group 2 Health Protective Constituents are below the Risk Level A values identified in Table 2 in Exhibit C, in each case in two consecutive pre-injection tests, the Biomethane may be injected subject to compliance with the Periodic Testing (as defined below) requirements specified in Section 4.6. . g) The costs of Prepre-Injection Testinginjection testing, as well as any required subsequent testing, will shall be borne by Producer. . h) If the test results from the first pre-injection sample set do not identify any Health Protective Constituents above the Upper Action Levels or Pipeline Integrity Constituents above the Trigger Levels and the Gas Quality Parameters are below the Action Levels, the Biomethane may be injected into the Receipt Point Facilities while the results for the second sample set are evaluated. If the results from the second prePre-injection Injection sample set indicate a constituent is outside the acceptable limit as specified in Table 1 in Exhibit C, the Biomethane will be shut-shut- off and the Producer will shall make necessary modifications to lower the concentration value below the Trigger Level and restart Prepre-Injection Testing injection testing after a minimum seven (7) calendar- day period from the last testing sampling. Pre-injection Testing will not be performed until the Receipt Point Facilities have been constructed, tested, and commissioned by NW Natural.